Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Courses
Press/Media
Search by expertise, name or affiliation
The use of anti-angiogenic drugs for central retinal vein occlusion
Michael Waisbourd
*
,
Anat Loewenstein
*
Corresponding author for this work
Ophthalmology
Research output
:
Contribution to journal
›
Editorial
3
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The use of anti-angiogenic drugs for central retinal vein occlusion'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Antiangiogenic Agents
100%
Retinal Vein Occlusion
100%
Macular Edema
57%
Visual Acuity
42%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
28%
Treatment Duration
14%
Israeli Society
14%
Further Treatment
14%
Common Cause
14%
Edema
14%
Personal Communication
14%
Non-ischemic
14%
Withholding
14%
Therapeutic Challenges
14%
Prospective Controlled Study
14%
Recommended Treatment
14%
Drug Injection
14%
Decreased Vision
14%
Visual Loss
14%
Intravitreal Anti-vascular Endothelial Growth Factor Injection
14%
Neovascular Glaucoma
14%
When to Start
14%
Anti-vascular Endothelial Growth Factor Therapy
14%
Optical Coherent Tomography
14%
Macular Ischemia
14%
Ocular Neovascularization
14%
Medicine and Dentistry
Angiogenesis Inhibitor
100%
Central Retinal Vein Occlusion
100%
Macular Edema
57%
Vasculotropin
42%
Visual Acuity
42%
Epileptic Absence
14%
Edema
14%
Ischemia
14%
Visual Impairment
14%
Tomography
14%
Drug Administration
14%
Neovascular Glaucoma
14%
Pharmacology, Toxicology and Pharmaceutical Science
Angiogenesis Inhibitor
100%
Central Retina Vein Occlusion
100%
Macular Edema
57%
Vasculotropin
42%
Epileptic Absence
14%
Ischemia
14%
Visual Impairment
14%
Neovascularization (Pathology)
14%
Edema
14%
Neovascular Glaucoma
14%